FDA Declines Approval for Novel Lung Cancer Treatment Developed in China
Federal regulators have turned down an application for ivonescimab, an experimental lung cancer therapy invented in China and licensed by a U.S. firm, citing insufficient evidence of prolonged overall survival in clinical trials.
🧠AI AnalysisPhoto: The New York Times Health
Key points
- The FDA rejected ivonescimab because it did not significantly prolong patient lives in global trials.
- The drug successfully delayed cancer progression when combined with chemotherapy.
- Summit Therapeutics holds the U.S. rights to the medication originally invented by Akeso Biopharma.
Federal Regulators Decline Application for Ivonescimab
The Food and Drug Administration has decided not to approve ivonescimab, a novel intravenous cancer treatment invented by the Chinese drugmaker Akeso Biopharma and licensed for the U.S. market by Florida-based Summit Therapeutics. Regulators pointed out that the global clinical trial, which enrolled patients across North America, Europe, and Asia who had already undergone targeted therapy, failed to demonstrate a statistically significant benefit in extending patients' overall lives.
While the international study showed that combining ivonescimab with chemotherapy successfully delayed cancer progression compared to chemotherapy alone, the company's subsequent unscheduled analyses of longer-term outcomes failed to persuade the agency. Summit representatives argued that slow study enrollment skewed the survival data. The intravenous medication works through a dual mechanism designed to activate the immune system while simultaneously cutting off the tumor's blood supply.
What to know: Ivonescimab remains under investigation in numerous other late-stage clinical trials targeting various tumor types, including colon, bladder, and breast cancers. Patients considering participation in clinical trials or exploring alternative therapies should always consult their oncologist for personalized medical guidance.
Source The New York Times Health — nytimes.com/2026/11/15/business/fda-lung-cancer-drug-china.html ↗
Read next
🏃FitnessUnderstanding and Addressing Love Handles Through Lifestyle Changes
Experts clarify that spot reduction of fat is not physiologically possible, recommending a combination of calorie management and high-intensity interval training instead.
🏃FitnessCiele Releases New Woolmark-Certified Merino Winter Running Apparel
Montreal-based brand Ciele has launched its second collection of merino wool running gear, featuring performance-focused fabrics designed for cold-weather training.
🏥Public HealthPreventive Services Task Force Resumes Meetings Under New Leadership
The U.S. Preventive Services Task Force is set to reconvene this week for the first time in over a year following a significant membership overhaul by Health Secretary Ro…
❤️Conditions & CareBlood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma
Researchers have identified a specific RNA signature in blood plasma that may help predict how well lymphoma patients respond to CAR T-cell therapy.
🧠Mind & Mental HealthAddressing Body Image and the Reality of Gluteal Anatomy
A personal reflection on the social and psychological impact of body shape, specifically regarding the gluteal region, and the limitations of consumer solutions for perce…
❤️Conditions & CareMigraine and Smoking Linked to Increased Early Stroke Risk in Women
A large-scale study suggests that people who have given birth and experience migraines while also smoking face a significantly higher risk of stroke before age 60.